NICE Attention Turns To Roche's Perjeta After Finally Passing Kadcyla
Executive Summary
After okaying Roche's advanced breast cancer therapy Kadcyla after four years of deliberation, the UK's HTA NICE will now decide how to respond to the Swiss group's proffered patient access scheme for Perjeta.
You may also be interested in...
NICE Reverses View On Perjeta In Breast Cancer After Roche's Price Cut
The UK's HTA NICE says it is now backing Roche's Perjeta (pertuzumab) to treat a certain form of breast cancer on the publicly funded NHS after Roche offered a price discount.
Frustrated Roche Hopes NICE Will Eventually Back Kadcyla
Roche Holding AG hopes the UK's National Institute for Health and Care Excellence will continue seeking possible ways to provide the Swiss drug maker's breast cancer therapy Kadcyla (ado-trastuzumab emtansine) on the publicly-funded National Health Service despite rejecting it in final guidance on cost grounds.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.